Loading…
Jade Biosciences, Inc. is projected to rise to $29.33 by 2027, a +49% move from its current price of $19.75. JBIO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $19.13 | $19.77 | $20.43 | +0.11% |
| Aug 3 | $18.90 | $19.79 | $20.74 | +0.23% |
| Aug 4 | $18.72 | $19.82 | $20.98 | +0.34% |
| Aug 5 | $18.58 | $19.84 | $21.19 | +0.45% |
| Aug 6 | $18.45 | $19.86 | $21.38 | +0.57% |
| Aug 7 | $18.35 | $19.88 | $21.55 | +0.68% |
| Aug 8 | $18.25 | $19.91 | $21.72 | +0.80% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $18.25 | $19.91 | $21.72 | +0.80% |
| Week 2 | $17.74 | $20.07 | $22.69 | +1.60% |
| Week 3 | $17.40 | $20.23 | $23.52 | +2.41% |
| Week 4 | $17.13 | $20.39 | $24.26 | +3.23% |
| Week 5 | $16.92 | $20.55 | $24.96 | +4.05% |
| Week 6 | $16.74 | $20.71 | $25.64 | +4.88% |
| Week 7 | $16.59 | $20.88 | $26.29 | +5.72% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial.
The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc.
is based in Waltham, Massachusetts.
Jade Biosciences, Inc. is categorized in Healthcare. These core activities define its research focus and pipeline development within the biotech sector, centered on inflammation and immunology in autoimmune diseases.
Overall, the description aligns Jade Biosciences with ongoing monoclonal antibody programs and collaborations, anchored in a Massachusetts-based biotech framework.
Jade Biosciences, Inc. (JBIO) is a healthcare company with a current price of $19.67 and a market cap of $1.2B, ranking 2284. The stock presents a bullish price outlook based on a multi-year forecast that moves from a 2026 average of $19.67 toward higher targets in later years.
Forecasts show a path of rising averages: 2027 $29.01, 2028 $31.57, 2029 $36.50, and 2030 $43.71, with conspicuously higher upside thereafter. The model indicates increasingly strong returns, culminating in a 2050 average of $345.23 and a 1655.1% ROI, with sentiment consistently described as BULLISH in later years.
These numbers place Jade Biosciences on a growth trajectory within its biotech niche, reflecting elevated expectations for its clinical programs and collaborations over time.
A major floor 32.9% below — a decisive break under it would weaken the trend.
The nearest floor, 14.8% below — buyers have tended to step in here.
The nearest ceiling, 14.1% above — a clean break opens room to run.
A major ceiling 35.9% above — clearing it would confirm fresh momentum.
Key JBIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of JBIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $19.75 | Sell | $19.80 | Sell |
| MA 10 | $19.85 | Sell | $20.00 | Sell |
| MA 20 | $20.70 | Sell | $20.24 | Sell |
| MA 50 | $19.87 | Sell | $20.22 | Sell |
| MA 100 | $19.72 | Buy | $19.44 | Buy |
| MA 200 | $16.52 | Buy | $23.27 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.17 | Neutral |
| Stoch RSI (14) | 22.53 | Neutral |
| CCI (20) | -72.59 | Neutral |
| Williams %R (14) | -84.06 | Info |
| MACD (12,26,9) | -0.16 | Sell |
| ROC (12) | -9.65 | Sell |
| Bollinger %B (20,2) | 0.26 | Neutral |
| Stochastic %K (14) | 15.94 | Buy |
| TRIX (15) | 0.01 | Buy |
| Awesome (5,34) | -0.53 | Sell |
| Ultimate (7,14,28) | 45.91 | Neutral |
| Momentum (10) | -1.11 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 19.65 | Buy |
| ADX (14) | 12.89 | Neutral |
| ATR (14) | 0.54 | Info |
The 30-day technical picture is labeled BULLISH, with RSI(14) at 40. The near-term moving averages show a SMA50 of $20.63 and a SMA200 of $16.03. There is technical support at $14.98 and resistance at $22.53, framing a constructive but cautious near-term setup.
The stock has traded within a 30-day range of $15.11 to $25.60, illustrating notable volatility within the near term. Annualized volatility stands at 80%, underscoring the possibility of wide price swings in short windows.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $13.12 | $19.75 | $28.23 | 0% | Neutral | |
| $22.96 | $29.33 | $39.88 | +49% | Bullish | |
| $24.74 | $32.73 | $46.50 | +66% | Bullish | |
| $27.89 | $37.98 | $55.83 | +92% | Bullish | |
| $33.65 | $47.01 | $71.09 | +138% | Bullish | |
| $33.96 | $48.57 | $75.29 | +146% | Bullish | |
| $43.65 | $63.80 | $101.10 | +223% | Bullish | |
| $58.78 | $87.71 | $141.78 | +344% | Bullish | |
| $61.85 | $94.10 | $154.93 | +376% | Bullish | |
| $67.95 | $105.37 | $176.43 | +434% | Bullish | |
| $110.64 | $187.05 | $336.04 | +847% | Bullish | |
| $202.47 | $398.89 | $793.14 | +19.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $13.12 | $19.75 | $24.14 | +0.00% |
| September 2026 | $17.78 | $21.16 | $25.99 | +7.15% |
| October 2026 | $18.25 | $21.90 | $27.25 | +3.50% |
| November 2026 | $18.00 | $21.75 | $27.33 | -0.70% |
| December 2026 | $18.31 | $22.26 | $28.23 | +2.34% |
Click any year to see its month-by-month JBIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect JBIO to range from $13.12 to $28.23 through 2026. The $19.75 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The JBIO price prediction for 2027 points to an average of $29.33 (low $22.96, high $39.88) — a potential gain of +49% on today's $19.75. Momentum favours further upside here.
In 2028, JBIO is projected to trade between $24.74 and $46.50, averaging $32.73 — a potential gain of +66% from today's $19.75. That is up +12% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Jade Biosciences, Inc.'s 2029 outlook centres on $37.98, within a $27.89 to $55.83 range. That is up +16% on the projected 2028 average. That marks a +92% change versus current levels. Momentum favours further upside here.
By 2030, JBIO could reach as high as $71.09, with a base case around $47.01 and support toward $33.65 — roughly +138% from $19.75. Buyers look set to stay in control over this stretch.
Expect JBIO to range from $33.96 to $75.29 through 2031. The $48.57 average target implies a +146% move from current prices. That is up +3% on the projected 2030 average. Momentum favours further upside here.
The JBIO price prediction for 2032 points to an average of $63.80 (low $43.65, high $101.10) — a potential gain of +223% on today's $19.75. Buyers look set to stay in control over this stretch.
In 2033, JBIO is projected to trade between $58.78 and $141.78, averaging $87.71 — a potential gain of +344% from today's $19.75. That is up +37% on the projected 2032 average. Momentum favours further upside here.
Jade Biosciences, Inc.'s 2034 outlook centres on $94.10, within a $61.85 to $154.93 range. That is up +7% on the projected 2033 average. That marks a +376% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, JBIO could reach as high as $176.43, with a base case around $105.37 and support toward $67.95 — roughly +434% from $19.75. Momentum favours further upside here.
Expect JBIO to range from $110.64 to $336.04 through 2040. The $187.05 average target implies a +847% move from current prices. That is up +78% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The JBIO price prediction for 2050 points to an average of $398.89 (low $202.47, high $793.14) — a potential gain of +19.2x on today's $19.75. Momentum favours further upside here.
Investing $1,000 in JBIO today (≈ 50.632911 JBIO) could be worth
$20,196.91
+$19,196.91 (+1920%) by 2050 · US Dollar
Based on the average projected JBIO price of $398.89 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in JBIOwould be worth at today's price.
$1,000 invested in JBIO on Jul 31, 2025 (≈ 139.082057 JBIO) would be worth
$2,746.87
+$1,746.87 (+174.7%) today · 2.75× · US Dollar
Based on a JBIO entry price of $7.19 vs. today's $19.75.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $20.08 | $983.57 | -1.6% |
| 1 month ago | $21.81 | $905.55 | -9.4% |
| 3 months ago | $24.23 | $815.11 | -18.5% |
| 6 months ago | $16.65 | $1,186.19 | +18.6% |
| 1 year ago | $7.19 | $2,746.87 | +174.7% |
| All time (5.0y) ago | $483 | $40.89 | -95.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our JBIO forecast.
Our base-case forecast reaches $40.00 around 2030.
Implied market cap at $40.00: $2.43B
Looking ahead, the multi-year forecast shows a sustained bullish tilt with rising average prices and substantial ROI growth. In 2027 the average is projected at $29.01 with a 47.5% ROI, followed by 2028 at $31.57 (60.5% ROI) and 2029 at $36.50 (85.6% ROI).
By 2030, the average rises to $43.71 with a 122.2% ROI, and 2031 is $43.06 with an 118.9% ROI. The trajectory continues through 2032 at $59.22 (201.1% ROI) and 2033 at $82.29 (318.4% ROI), then 2034 at $85.52 (334.8% ROI) and 2035 at $96.82 (392.2% ROI).
Key later milestones include 2040 with an average of $164.87 and a 738.2% ROI, and 2050 with an average of $345.23 and a 1655.1% ROI. Sentiment in these years is described as BULLISH. These figures are estimates and not guarantees.
Tap a question to reveal the answer.
In 2030 the forecasted average price is $43.71, with a min of $29.80 and a max of $69.49, and a ROI of 122.2%; sentiment is BULLISH.
The forecast shows bullish sentiment in multiple years with rising averages (e.g., 2027 average $29.01, 2029 $36.50, 2030 $43.71) and higher ROIs (up to 122.2% by 2030 and much higher by 2040 and 2050), though these are estimates and not guarantees.
Yes, the forecast implies it could surpass $100 by 2040, with a 2040 average of $164.87 and a 738.2% ROI; prior years peak below $100 (e.g., 2033 $82.29, 2035 $96.82).
Current price is $19.67 and market cap is $1.2B.
RSI(14) is 40, SMA50 is $20.63, SMA200 is $16.03, with support at $14.98 and resistance at $22.53. The 30-day range is $15.11 to $25.60 and volatility is 80%.
Jade Biosciences, Inc. Community Discussion
0Share your Jade Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.